-
Mashup Score: 7How I approach the prevention and treatment of thrombotic complications in hospitalized patients - 9 month(s) ago
Associate Editors Hendrickson and Ortel edited a How I Treat series on inpatient consultative hematology. In this timely series of articles, the authors present
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0How I approach bleeding in hospitalized patients - 9 month(s) ago
Associate Editors Hendrickson and Ortel edited a How I Treat series on inpatient consultative hematology. In this timely series of articles, the authors present
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
How I approach #bleeding in hospitalized patients #ConsultativeHematology -> an essential series! 👉https://t.co/cEPmAtWNI9 @BloodJournal @Bsamuelson_md https://t.co/QYaTafemV1
-
-
Mashup Score: 0CHP/CCUS: Low blood cancer risk for most patients - 9 month(s) ago
The goal of ongoing research is to prevent CHIP/CCUS progression in higher-risk patients.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#CHP/#CCUS: Low #BloodCancer risk for most patients 👉https://t.co/NbhVrSgr2b @MDedgeHemOnc @MAlexanderOtto #CHIP https://t.co/b2b7JG4MbV
-
-
Mashup Score: 0Cruel summer for medical students and Taylor Swift fans - 9 month(s) ago
Medical students applying for residency tend to be as stressed out as Swifties trying to score concert tickets.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Cruel summer for #MedicalStudents and Taylor Swift fans 👉https://t.co/x8934IL7ep @MDedgeHemOnc #ERAS https://t.co/Fgy6nCD5Sy
-
-
Mashup Score: 0Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study - 9 month(s) ago
Key Points. DMF treatment shows good efficacy in treatment of patients with CTCL, especially for Sézary syndrome with high tumor load.The tolerability of DMF in
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#DimethylFumarate treatment in relapsed and refractory cutaneous #TcellLymphoma: a multicenter phase 2 study 👉https://t.co/8WMJs6uSGx @BloodJournal @HeidelbergU🇩🇪 https://t.co/g8SpOZThZF
-
-
Mashup Score: 0Q&A: What to know about the new BA 2.86 COVID variant - 9 month(s) ago
BA 2.86 is a subvariant of Omicron, but according to reports from the CDC, the strain has many more mutations than the ones that came before it.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Q&A: What to know about the new #BA286 #COVID variant So far only 26 cases have been identified. 👉https://t.co/JBhMIcJR8u @MDedgeHemOnc #Variant https://t.co/RufAtvBbGw
-
-
Mashup Score: 0‘Game changer’ data for vitamin D in digestive tract cancers - 9 month(s) ago
In the p53-immunoreactive subgroup, daily vitamin D supplementation reduced the risk of relapse or death by 73%.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
‘Game changer’ data for vitamin D in digestive tract cancers 👉https://t.co/4x3l6WsyA4 @MDEdgeHemOnc #AMATURASU https://t.co/7dJY4Rp9kH
-
-
Mashup Score: 0New trials in prostate cancer: Could your patient benefit? - 9 month(s) ago
Several new trials have opened in recent months.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
New trials in #ProstateCancer: Could your patient benefit? 👉https://t.co/ehuvFBlfUF @MDedgeHemOnc @Leask_helen https://t.co/yGP3SB81UM
-
-
Mashup Score: 0Breast cancer: Hope in sight for improved tamoxifen therapy? - 9 month(s) ago
Eventually, the idea is to combine treatment with antiestrogens with a medicinal product that promotes localization of PRMT5 in the nucleus to guarantee response to tamoxifen.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#BreastCancer: Hope in sight for improved #TamoxifenTherapy? 👉https://t.co/8A2cFnQaGG @MDEdgeHemOnc #CRCL https://t.co/Y4BhAfj4PF
-
-
Mashup Score: 0A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma - 9 month(s) ago
Key Points. Pembrolizumab is effective as consolidative therapy for patients with PTCL in first remission.Pembrolizumab administered after ASCT has an acceptabl
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
A phase 2 study of #Pembrolizumab after autologous #StemCell transplantation in patients with T-cell #NonHodgkinLymphoma 👉https://t.co/hSHeMa4o66 @Blood https://t.co/RzxgbyahGj
-
How I approach the #prevention and #treatment of #ThromboticComplications in hospitalized patients 👉https://t.co/7IFn11TmJu @BloodJournal @Bhwords #VTE https://t.co/IkOf9wvchF